Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00566423 · ClinicalTrials.gov registry record · NA
Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)
A NA study of Pulmonary Arterial Hypertension, sponsored by Northwell Health.
- Completed
- Registry status
- NA
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT00566423: Completed NA study of Pulmonary Arterial Hypertension, sponsored by Northwell Health.
NCT00566423 is a NA study of Pulmonary Arterial Hypertension that has completed, run by Northwell Health. The registered enrollment target is 75 participants, below the 461-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00566423, a NA study of Pulmonary Arterial Hypertension, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesize that baseline plasma brain natriuretic peptide (BNP) and migration inhibitory factor (MIF) levels are surrogate markers of clinical severity of PAH and that changes in plasma brain natriuretic peptide (BNP) and MIF levels pre and post exercise.
Conditions Studied
Interventions
- OTHER Blood draw
Study Locations (1)
New York
- North Shore-Long Island Health System - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-06 |
| Phase | NA |
What the finished NCT00566423 record still lists
NCT00566423 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 461-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Blood draw is the first listed.
NCT00566423 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00566423 about?
NCT00566423 is a clinical study titled "Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)". The investigators hypothesize that baseline plasma brain natriuretic peptide (BNP) and migration inhibitory factor (MIF) levels are surrogate markers of clinical severity of PAH and that changes in plasma brain natriuretic peptide (BNP) and MIF levels pre and post exercise.
What is the current status of trial NCT00566423?
This trial is currently completed. It is a NA study. The enrollment target is 75 participants. The study started on 2007-05. Estimated completion is 2010-06.
What conditions does trial NCT00566423 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT00566423?
The interventions under investigation include: Blood draw (OTHER).
Who is sponsoring clinical trial NCT00566423?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00566423 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00566423's enrollment target sits among peer trials
75 22nd of 63 higher than 42 of 63 other Pulmonary Arterial Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Arterial Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
RECRUITING · NA
-
Mobile Health Intervention to Improve Exercise in Pediatric PH
RECRUITING · NA
-
A Study of Pulmonary Hypertension Peripheral Limitations
RECRUITING · NA
-
Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)
RECRUITING · NA
-
Safety and Impact of Low Resistance Exercise Training on Quality of Life in Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia